PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.04%
R&D change of 23.04% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
21.61%
G&A change of 21.61% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.65%
Operating expenses change of 22.65% versus flat Biotechnology costs. Walter Schloss would verify control.
22.65%
Total costs change of 22.65% versus flat Biotechnology costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
3.49%
D&A change of 3.49% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
-23.08%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-22.65%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-58.12%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-23.20%
Pre-tax income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.20%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-16.67%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-22.50%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
5.52%
Share count reduction below 50% of Biotechnology median of 0.15%. Jim Chanos would check for issues.
0.56%
Diluted share change of 0.56% versus stable Biotechnology. Walter Schloss would verify approach.